Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
SSE:600332
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
24.59
33.06
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
Net Income (Common)
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
SSE:600332
|
Net Income (Common)
¥3.4B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
2%
|
CAGR 10-Years
13%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Net Income (Common)
¥3.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Net Income (Common)
¥3.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
18%
|
CAGR 10-Years
23%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Net Income (Common)
¥5.4B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
2%
|
CAGR 10-Years
14%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Net Income (Common)
¥4.3B
|
CAGR 3-Years
5%
|
CAGR 5-Years
3%
|
CAGR 10-Years
6%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Net Income (Common)
-¥780.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
Glance View
Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. stands as a prominent player in China's healthcare industry, weaving a rich legacy that dates back to its formation in the 20th century. Rooted in the dynamic city of Guangzhou, Baiyunshan reflects a harmonious blend of traditional Chinese medicine (TCM) and modern pharmaceutical innovation. The company's name itself, Baiyunshan—meaning "White Cloud Mountain" in Chinese—symbolizes its foundational connection to the city's cultural heritage and its aspiration to elevate healthcare standards. Baiyunshan's operations are a testament to its multifaceted approach to pharmaceutical production. It delves into the research and development, manufacturing, and distribution of both TCM and Western medicine. This dual approach enables Baiyunshan to cater to a diverse demographic, forging a unique path by merging ancient medical wisdom with cutting-edge scientific advancements. The core of Baiyunshan's business strategy pivots around its expansive product portfolio, which is instrumental in its revenue generation. Pharmaceuticals are at its heart, encompassing a wide range of products from patent medicines to essential drugs that are household names in China. Additionally, the company has successfully branched into the production of over-the-counter (OTC) products, health supplements, and even skincare products, broadening its consumer reach. Meanwhile, Baiyunshan's distribution network—extensive and strategically aligned—stretches across domestic and international markets, ensuring its products are widely accessible. By leveraging strategic partnerships and ongoing innovation, the company continually fortifies its market presence, making Baiyunshan a notable financial performer and a beacon of trust in the healthcare industry.
See Also
What is Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd's Net Income (Common)?
Net Income (Common)
3.4B
CNY
Based on the financial report for Sep 30, 2024, Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd's Net Income (Common) amounts to 3.4B CNY.
What is Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
13%
Over the last year, the Net Income (Common) growth was -20%. The average annual Net Income (Common) growth rates for Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd have been -1% over the past three years , 2% over the past five years , and 13% over the past ten years .
You don't have any saved screeners yet
